Transarterial radioembolization in hepatocellular carcinoma
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer International Publishing
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and fourth most common cause of cancer-related deaths worldwide. For early-stage HCC patients, liver transplantation (LT) is the best choice because it reduces new HCC lesions due to the treatment of liver cirrhosis. But every patient is not a candidate for LT because of suitability of the patient (tumor size, macrovascular invasion, etc.) and availability of organ. For these unsuitable patients, there are nonsurgical treatment options such as transarterial embolization (TAE), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), radiofrequency ablation (RFA), microwave ablation (MWA), and stereotactic body radiation therapy (SBRT). TARE is one of the interventional oncology procedures for unresectable HCC patients. It is a form of brachytherapy which allows localized radiotherapy to the liver tumors limiting the dose to the normal parenchyma. The isotope Yttrium-90 (90Y), embedded onto glass or resin microspheres, is given to the vessels which supply the tumor. Due to this selectivity of the procedure, TARE is a safe and effective treatment for unresectable HCC patients. There are advantages of TARE to the other locoregional therapies: It is an outpatient procedure; due to the minimal embolic effect, it may be performed to the cases with portal venous invasion which is contraindication of chemoembolization; and postembolization syndrome is seen rarely. Also, the main goal of TARE is downstaging the tumor for resection and liver transplantation and bridging to transplantation. It has an important role in every stages of HCC. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2021. All rights reserved.
Açıklama
Anahtar Kelimeler
Hepatocellular carcinoma, Radioembolization, TARE
Kaynak
Liver Cancer in the Middle East
WoS Q Değeri
Scopus Q Değeri
N/A
